Table 4.
Analyses of the participants experiencing hospitalization, emergency room visit or death with subgroups based upon different at-risk definitions.
| Placebo | NTZ | OR (95% CI) | P-value | Relative Reduction | |
|---|---|---|---|---|---|
| All SARS-CoV-2-Positive Participants | 6/195 (3·1%) | 1/184 (0·5%) | 4·7 (0·6–39·7) | 0·11 | 82% |
| Subgroups: | |||||
| “May Be” or “At Increased Risk” for Severe COVID-19 Illness per CDC (protocol-defined stratification factor) | 6/126 (4·8%) | 1/112 (0·9%) | 5·6 (0·7–46·8) | 0·08 | 81% |
| At Increased Risk for Severe COVID-19 Illness per CDC | 6/121 (5·0%) | 1/104 (1·0%) | 5·4 (0·6–45·4) | 0·09 | 81% |
| At High Risk of Progressing to Severe COVID-19 and/or Hospitalization (per EUA documents for monoclonal antibodies)1 | 5/69 (7·2%) | 1/60 (1·7%) | 4·6 (0·5–40·6) | 0·13 | 77% |
1
≥ 65 years of age, BMI ≥35 kg/m2, chronic kidney disease, diabetes, immunosuppressive disease, current receipt of immunosuppressive treatment, or ≥55 years of age with at least one of cardiovascular disease, hypertension, or chronic obstructive pulmonary disease or another chronic respiratory disease.